Reported Earlier, Tyra Biosciences Announces Preliminary Clinical Proof-of-Concept Results For TYRA-300 In Phase 1/2 SURF301 Study For Metastatic Urothelial Cancer (mUC) Patients
Portfolio Pulse from Benzinga Newsdesk
Tyra Biosciences announced promising preliminary results for its TYRA-300 drug in a Phase 1/2 study for metastatic urothelial cancer. The study showed a 54.5% partial response rate and 100% disease control in patients, with positive safety outcomes.
October 25, 2024 | 6:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tyra Biosciences' TYRA-300 shows promising results in a Phase 1/2 study for metastatic urothelial cancer, with a 54.5% partial response rate and 100% disease control. Positive safety results were also reported.
The announcement of positive preliminary results for TYRA-300 in a clinical study is likely to boost investor confidence in Tyra Biosciences. The high partial response rate and disease control, along with positive safety outcomes, suggest potential for future success and market approval, which could positively impact the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100